Match!
Zoltan Lohinai
Medical University of Vienna
PathologyLung cancerLungAdenocarcinomaMedicine
29Publications
5H-index
130Citations
What is this?
Publications 32
Newest
#1David Dora (Semmelweis University)H-Index: 2
#2Christopher J. Rivard (Anschutz Medical Campus)H-Index: 35
Last. Zsolt Megyesfalvi (Semmelweis University)H-Index: 1
view all 14 authors...
Small cell lung cancer (SCLC) has recently been sub-categorized into neuroendocrine (NE)-high and NE-low subtypes showing 9immune desert9 and 9immune oasis9 phenotypes, respectively. We aimed to characterize the immune cell localization and the microenvironment according to immune checkpoints and NE subtypes in human SCLC tissue samples at the protein level. In this cross-sectional study, we included 32 primary tumors and matched lymph node (LN) metastases of resected early-stage, histologically...
Source
#1Zoltan LohinaiH-Index: 5
#2Zsolt MegyesfalviH-Index: 1
Last. Fred R. HirschH-Index: 75
view all 10 authors...
Background: Recent preclinical data suggest that neuroendocrine (NE) subtype of small cell lung cancer (SCLC) has strong therapeutic relevance. NE high tumors are associated with immune desert and NE low tumors are considered to have an immune oasis phenotype. Our aim was to investigate the NE phenotypes of surgically resected SCLC tumors according to inter-tumor heterogeneity. Methods: Expression analysis for 2,560 genes was performed in 32 surgically resected SCLC patients’ primary tumors and ...
1 CitationsSource
#1Zoltan Lohinai (Medical University of Vienna)H-Index: 5
#2Zsolt Megyesfalvi (Semmelweis University)H-Index: 1
Last. Glen J. WeissH-Index: 35
view all 4 authors...
Abstract BACKGROUND: Molecular underpinnings that may prognosticate survival could increase understanding of small cell lung cancer (SCLC) tumor behavior. Here, we report the clinicopathological characteristics and biomarker profiles of short-term (ST) versus long-term (LT) survival in patients with metastatic SCLC. METHODS: Of the 876 consecutive metastatic SCLC patients receiving standard of care therapy, 44 met the definition of LT and 91 for ST, respectively. Available FFPE tumor tissue bloc...
1 CitationsSource
#1Áron GhimessyH-Index: 2
Last. Balazs DomeH-Index: 28
view all 18 authors...
Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angiogenesis has been well established, its prognostic and predictive role in the above setting remains unclear. The association between KRAS exon 2 mutational status and clinicopathological variables inc...
Source
Source
#1Judit MoldvayH-Index: 11
#2Vanda TéglásiH-Index: 3
Last. Lilla ReinigerH-Index: 10
view all 14 authors...
Source
#1Zoltan LohinaiH-Index: 5
#2Zsolt MegyesfalviH-Index: 1
Last. Fred R. HirschH-Index: 75
view all 9 authors...
Source
Source
#1Zsolt MegyesfalviH-Index: 1
#2Zoltan LohinaiH-Index: 5
Last. Balazs DomeH-Index: 28
view all 3 authors...
Source
#1Zoltan LohinaiH-Index: 5
#2Yoshitaro HeshikiH-Index: 2
Last. Glen J. WeissH-Index: 35
view all 10 authors...
Source
1234